Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 10.6028
- Book/Share 4.2989
- PB 15.8203
- Debt/Equity 2.998
- CurrentRatio 1.5871
- ROIC 0.281
- MktCap 7997771970.0
- FreeCF/Share 5.1391
- PFCF 13.2765
- PE 13.3874
- Debt/Assets 0.6801
- DivYield 0
- ROE 1.4155
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HALO | Leerink Partners | Underperform | Market Perform | -- | $70 | Oct. 14, 2025 |
| Upgrade | HALO | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Aug. 6, 2025 |
| Resumed | HALO | Goldman | -- | Neutral | -- | $55 | July 10, 2025 |
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Read More
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
Read More
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Halozyme Just Bought Its Next Decade Of Growth
Published: October 23, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for ≤2 mL self-injections, complementing ENHANZE rather than cannibalizing it. Existing partners like Lilly, Argenx, and J&J are already aligned, with first-in-human Hypercon studies expected within 12–15 months.
Read More
Halozyme to Report Third Quarter 2025 Financial and Operating Results
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m.
Read More
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Read More
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Read More
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, …
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Read More
5 Biotech Stocks Worth Adding to Your Portfolio Now
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Read More
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Read More
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Read More
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone. Welcome to Morgan Stanley's Global Healthcare Conference.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
Read More
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Read More
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for September 3rd
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Read More
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Read More
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Identify Superstar Stocks Like Halozyme with Money Flows
Published: August 29, 2025 by: FXEmpire
Sentiment: Positive
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Read More
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma," said Dr. Helen …
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees 350